Roche’s CT-388 phase 2 obesity results show 22.5% weight loss and solid tolerability vs tirzepatide—plus what’s next for ...

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

Genetic conditions with actionable interventions affect nearly 10% of populations in the United States and internationally - if one includes both common ...

A Juneau boy with a rare genetic disease will be able to receive potentially life-changing gene therapy after local residents raised more than $1 million this fall. For the past two years, 4-year-old ...

The home- and community-based services industry has changed drastically over the last decade, from different payer mixes to new service line opportunities. To navigate Medicaid budget cuts and other ...

For too long, we’ve tried to solve deeply rooted social challenges with disconnected solutions, using one program for education, another for healthcare and a separate one for jobs. They often operate ...

The expert faculty transition to a discussion on emerging therapies for high-risk, Bacillus Calmette–Guérin (BCG)-naïve non–muscle invasive bladder cancer (NMIBC), focusing on the wave of ongoing ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, drugmaker Novo Nordisk ...

SIOUX FALLS, S.D. (KELO) — The US Curling Olympic Trials wrapped up at the Premier Center Sunday night with Team Casper defeating Team Shuster in a winner-take-all third game. With Casper’s win, that ...

Bristol Myers Squibb is expanding a partnership with oncology organization Sarah Cannon Research Institute (SCRI), tapping into the institute’s community-based clinical trial network. BMS will plug ...

Advances in MM management have improved survival, but challenges remain for patients progressing after three therapy lines. New therapies like CAR T-cell and bispecific antibodies require integration ...